Home > Insider Trading > Filing (0000899243-19-015281)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1399529	Dicerna Pharmaceuticals Inc	DRNA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1578965	Adam Koppel	200 Clarendon Street Boston MA 02116	Yes	No	Yes	No
1687968	Bain Capital Life Sciences Fund, L.p.	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702921	Bcip Life Sciences Associates, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702957	Lawrence Jeffrey Schwartz	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703030	Bain Capital Life Sciences Partners, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-05-29	1,600,000	$12.50	7,330,237	No	4	S	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnotes

Footnotes

On May 29, 2019, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") sold 1,447,289 and 152,711 shares of common stock, respectively, directly to a private investor.
Dr. Koppel is a director of the Issuer.
Bain Capital Life Sciences Partners, LP ("BC LS P") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.